A major goal of the DF/HCC GI SPORE is to identify and fund projects that will lead to clinically testable hypotheses aimed at reducing the incidence and mortality rate of GI cancers or improving the quality of life of patients with GI cancers. The Developmental Research Program (DRP) supports short-range studies to establish the results needed to facilitate well-validated, hypothesis-driven translational projects. Although the DRP funds established investigators, an important goal is to identify and stimulate interest in GI cancer research among groups whose current focus may be different but sufficiently related. The Developmental Projects Program is led a highly qualified committee of DF/HCC researchers who participate actively in the selection and ongoing review of pilot projects and who represent laboratory, population and clinical science across the Harvard institutions. The DRP provides the depth and flexibility required to maintain innovation in GI SPORE activities. During the prior funding cycle, the DF/HCC SPORE supported 18 highly innovative and productive developmental projects that have enabled novel discoveries and 29 successful grant applications to further their ongoing research. The DRP will continue to support novel research in GI cancer and has the following specific aims: 1. Solicit pilot projects in GI cancer translational research that have significant potential for reducing the incidence and mortality rate of GI cancer and/or improving the quality of life of patients with GI cancers. 2. Foster collaborative efforts among SPORE investigators and with other investigators to encourage the development of new and innovative ideas and approaches. 3. Monitor the progress of the projects and provide critical feedback. 4. Encourage and assist investigators with promising preliminary data developed with support of this Program to apply for extramural peer-reviewed funding. 5. When necessary or possible, promote the most promising projects in the Developmental Research Program to full SPORE research projects.
The DF/HCC GI SPORE Developmental Research Program seeks to support and nurture new innovative research efforts aimed at reducing the incidence and mortality rate of GI cancers or improving the quality of life of patients with GI cancers. To date, the Program has supported 18 novel and productive projects that are making meaningful discoveries in our understanding of GI cancer biology, prevention, and therapy.
|Russo, Mariangela; Siravegna, Giulia; Blaszkowsky, Lawrence S et al. (2016) Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discov 6:147-53|
|Kugel, Sita; SebastiÃ¡n, Carlos; Fitamant, Julien et al. (2016) SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b. Cell 165:1401-15|
|Kim, Sun A; Inamura, Kentaro; Yamauchi, Mai et al. (2016) Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. Br J Cancer 114:199-206|
|Delaney, Susan K; Hultner, Michael L; Jacob, Howard J et al. (2016) Toward clinical genomics in everyday medicine: perspectives and recommendations. Expert Rev Mol Diagn 16:521-32|
|Mima, Kosuke; Cao, Yin; Chan, Andrew T et al. (2016) Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location. Clin Transl Gastroenterol 7:e200|
|Whitley, Melodi Javid; Cardona, Diana M; Lazarides, Alexander L et al. (2016) A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci Transl Med 8:320ra4|
|Ahronian, Leanne G; Corcoran, Ryan B (2016) Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations. Mol Cell Oncol 3:e1048405|
|Saha, Supriya K; Zhu, Andrew X; Fuchs, Charles S et al. (2016) Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist 21:594-9|
|Ou, Wen-Bin; Lu, Minmin; Eilers, Grant et al. (2016) Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53. Br J Cancer 115:1253-1263|
|Lazarides, Alexander L; Whitley, Melodi J; Strasfeld, David B et al. (2016) A Fluorescence-Guided Laser Ablation System for Removal of Residual Cancer in a Mouse Model of Soft Tissue Sarcoma. Theranostics 6:155-66|
Showing the most recent 10 out of 481 publications